(#54) Multidimensional Impact of Tardive Dyskinesia Reported by Clinicians: Second Interim Analysis From the IMPACT-TD Registry

Abstract: Background: We previously assessed the multidimensional impact of tardive dyskinesia (TD) on an initial population of individuals (n=286) in the IMPACT-TD Registry. Here, we report results for the full IMPACT-TD Registry cohort at enrollment. Methods: The IMPACT-TD Registry, a phase 4, 3-year, longitudinal study, includes individuals aged ?18 years with a score of ?2 on at least 1 item of the Abnormal Involuntary Movement Scale (AIMS) and probable TD or, alternatively, who are receiving vesicular monoamine transporter 2 inhibitor therapy for TD. Clinicians assessed the multidimensional impact of TD (IMPACT-TD ClinRO scale) and severity of TD movements (AIMS and Clinical Global Impression of Severity of TD [CGIS-TD] scale). Results: As of December 31, 2024, the IMPACT-TD registry included 611 individuals (mean age 52.1 years; 53.5% female; 63.3% White). At enrollment, 95.1% of participants with ClinRO scores (n=577) experienced some impact of TD in any domain, and 74.7% experienced moderate/severe impact in any domain (social, 53.6%; psychological/psychiatric, 59.8%; physical, 51.0%; vocational/educational/recreational, 47.7%). Moderate/severe ClinRO impact in ?2 domains or in all 4 domains was reported for 61.9% and 29.1% of participants, respectively. Among participants with total motor AIMS scores 0ñ6 (n=251), 90.4% experienced some ClinRO impact, and 59.8% experienced moderate/severe impact in any domain. In participants with no/very mild/mild CGIS-TD scores (n=254) , 90.9% experienced some ClinRO impact, and 52.4% had moderate/severe impact of TD. Conclusions: In the full cohort enrolled in this large real-world study, clinicians reported that TD has multidimensional impact even in those with mild abnormal movement severity.Short Description: This real-world observational study of 611 individuals with tardive dyskinesia (TD) used the Abnormal Involuntary Movement Scale and the Clinical Global Impression of Severity of TD scale to assess TD movement severity and the clinician-reported IMPACT-TD scale to assess the functional impact of TD in social, psychological/psychiatric, physical, and vocational/educational/recreational domains. Clinicians reported that, at baseline, 95.1% of participants experienced impact of TD in any domain, and 74.7% experienced moderate/severe impact in any domain.Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC.